MA52290B1 - Thyroid hormone drug preparations of dry powder for inhaled administration - Google Patents
Thyroid hormone drug preparations of dry powder for inhaled administrationInfo
- Publication number
- MA52290B1 MA52290B1 MA52290A MA52290A MA52290B1 MA 52290 B1 MA52290 B1 MA 52290B1 MA 52290 A MA52290 A MA 52290A MA 52290 A MA52290 A MA 52290A MA 52290 B1 MA52290 B1 MA 52290B1
- Authority
- MA
- Morocco
- Prior art keywords
- dry powder
- thyroid hormone
- hormone drug
- inhaled administration
- preparations
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 4
- 239000000843 powder Substances 0.000 title abstract 3
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000005495 thyroid hormone Substances 0.000 title abstract 2
- 229940036555 thyroid hormone Drugs 0.000 title abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 abstract 1
- 229960001021 lactose monohydrate Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des compositions de poudre sèche appropriées pour une inhalation par l'intermédiaire d'un dispositif d'inhalation approprié, comprenant un médicament d'hormone thyroïdienne et un sucre non réducteur ou un alcool de sucre comme excipient unique. Les préparations selon l'invention présentent une stabilité supérieure à celle des préparations correspondantes comprenant du monohydrate de lactose, un excipient couramment utilisé pour des préparations de poudre sèche.The present invention relates to dry powder compositions suitable for inhalation through a suitable inhalation device, comprising a thyroid hormone drug and a non-reducing sugar or sugar alcohol as the sole excipient. The preparations according to the invention have a stability superior to that of the corresponding preparations comprising lactose monohydrate, an excipient commonly used for dry powder preparations.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18167617 | 2018-04-16 | ||
| PCT/EP2019/059123 WO2019201712A1 (en) | 2018-04-16 | 2019-04-10 | A pharmaceutical dry powder composition for inhalation comprising a thyroid hormone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52290A MA52290A (en) | 2021-02-24 |
| MA52290B1 true MA52290B1 (en) | 2022-05-31 |
Family
ID=62002591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52290A MA52290B1 (en) | 2018-04-16 | 2019-04-10 | Thyroid hormone drug preparations of dry powder for inhaled administration |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR114768A1 (en) |
| MA (1) | MA52290B1 (en) |
| TW (1) | TW201945035A (en) |
-
2019
- 2019-04-10 AR ARP190100950A patent/AR114768A1/en unknown
- 2019-04-10 MA MA52290A patent/MA52290B1/en unknown
- 2019-04-12 TW TW108112825A patent/TW201945035A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA52290A (en) | 2021-02-24 |
| AR114768A1 (en) | 2020-10-14 |
| TW201945035A (en) | 2019-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50205B1 (en) | Nicotine formulation | |
| MX2011011772A (en) | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies. | |
| MY121073A (en) | Pharmaceutical formulations for aerosols with two or more active substances | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| NZ600096A (en) | Formulations of antibody | |
| MA46665B1 (en) | Cyclic peptide tyrosine tyrosine compounds coupled to antibody as neuropeptide y receptor modulators | |
| EP1938814A4 (en) | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis | |
| SA517390550B1 (en) | Orodispersible Dosage Unit Containing an Estetrol Component | |
| MA43876B1 (en) | Pharmaceutical compositions and their uses against lysosomal storage diseases | |
| MX2021006751A (en) | Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat. | |
| PH12021550767A1 (en) | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation | |
| MX2022001724A (en) | Pharmaeutical composition comprising ensifentrine. | |
| US20220257628A1 (en) | Once-daily treatment of pulmonary fibrosis | |
| MX2017013950A (en) | Zolmitriptan powders for pulmonary delivery. | |
| MX2020010738A (en) | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos). | |
| MA52290B1 (en) | Thyroid hormone drug preparations of dry powder for inhaled administration | |
| WO2007011958A3 (en) | Intraoral dosage forms of glucagon | |
| MA45202B1 (en) | Pharmaceutical composition comprising a mineralocorticoid receptor antagonist and its use | |
| JP5781698B2 (en) | Rocuronium preparation with improved vascular pain, method for producing the same, and method for inhibiting / releasing vascular pain using the rocuronium preparation | |
| Esposito et al. | Successful treatment of cryptococcal meningitis with a combination of liposomal amphotericin B, flucytosine and posaconazole: two case reports | |
| ZA202200331B (en) | Naltrexone formulation | |
| MA46778A1 (en) | Intranasal composition comprising betahistine | |
| AU2019253577A1 (en) | Oxytocin compositions and methods of use | |
| MX2020010928A (en) | A pharmaceutical dry powder composition for inhalation comprising a thyroid hormone. | |
| PL432374A1 (en) | New inhalation therapeutic system delivering a reduced amount of fluticasone propionate and salmeterol with increased efficacy and safety profile |